Market Newsdesk

PLYMOUTH, Mich., April 08, 2026 (GLOBE NEWSWIRE) — Garrett Motion Inc. (Nasdaq: GTX), a global leader in differentiated turbocharging and electrification technologies, is showcasing its breakthrough oil-free centrifugal compressors engineered for data centers, battery energy storage systems (BESS), and wider industrial and commercial cooling applications at China Refrigeration Expo 2026 (April 8–10).

Garrett is launching a comprehensive portfolio of oil-free centrifugal compressors covering cooling demands from 7 to 500 tons (25 to 1,750 kWc), enabling scalable, high-efficiency cooling architectures. The platform combines high-speed centrifugal turbomachinery, oil-free foil bearings and model-based control algorithms, outperforming traditional scroll and screw designs. The portfolio, enabling reduced maintenance demands and superior total cost of ownership, marks Garrett’s expansion into next-generation ultra-low-GWP and high-efficiency industrial cooling solutions for the most demanding operating environments.

Among the lineup is a new large-capacity, 1,250 kWc compressor for high-performance data-center and industrial cooling systems, making its public debut at the show.

“Global demand for high-efficiency, low-environmental-impact cooling technologies is accelerating, and China remains one of the fastest-growing HVAC markets,” said Olivier Rabiller, President & CEO of Garrett Motion. “Garrett is leveraging its differentiated technologies, proven in demanding automotive applications, to deliver disruptive solutions that provide unique value for the next generation of HVAC systems.”

China’s rapidly expanding data center, BESS, and broader industrial and commercial refrigeration sectors are driving demand for higher-performance and eco-responsible thermal solutions. Garrett’s compressors deliver more than 10% real-world energy savings, support ultra-low-GWP refrigerants, and have a compact, retrofit-ready design for rooftop and unitary systems, (modular) chillers, and BESS applications.

Garrett will also present its oil-free cooling compressor for electric truck and bus applications, which is 50% smaller and 30% lighter than traditional solutions, and delivers efficient, low-vibration thermal management. Launch is planned with Cling for 2027.

Garrett welcomes OEMs, integrators, and industry partners to visit its booth (B2F86) at China Refrigeration Expo to explore collaboration opportunities across industrial, commercial, and mobility cooling markets.

About Garrett Motion Inc.

A differentiated technology leader, Garrett Motion has a 70-year history of innovation in the automotive sector (cars, trucks) and beyond (off-highway equipment, marine, power generators). Its well-recognized expertise in turbocharging has enabled significant reductions in engine size, fuel consumption, and CO₂ emissions. Garrett is committed to advancing turbo applications while leveraging its unique technology solutions, such as fuel cell compressors for hydrogen fuel cell vehicles, as well as electric propulsion and thermal management systems for automotive and industrial applications. Garrett has six R&D centers, 13 manufacturing facilities and a team of more than 8,700 employees in more than 20 countries. For more information, please visit www.garrettmotion.com.

About Garrett Motion China

Garrett established its presence in China in 1994 and was among the first global companies to introduce turbocharging technology into the country. Headquartered in Shanghai, Garrett has two world-class, advanced manufacturing facilities in Shanghai and Wuhan, as well as 2 innovation centers. The company employs more than 1,000 people, including a China R&D team of over 200 specialists with end-to-end engineering and service capabilities. Garrett boasts lasting partnerships with more than 30 global and Chinese automakers. It offers a comprehensive portfolio of turbocharging technology for gasoline, diesel, natural gas, hybrid and zero emission technology for battery electric vehicles in automotive sector and beyond.

CONTACTS:

Paris (France), April 8, 2026

Viridien upgraded to “B” by S&P,

following rating confirmations by Moody’s and Fitch

Viridien announces today that Standard & Poor’s (S&P) has upgraded its long-term credit rating to “B”, with a stable outlook, reflecting the Company’s solid operational execution. The previous rating was “B-” with a positive outlook. In parallel, the rating on the Company’s senior secured notes has been raised to “B+”, from “B” previously.

S&P highlighted that “the company has built a positive track record of more stable performance over the past couple of years in a volatile market environment, benefiting from the end of the costly Shearwater contract in 2025, as well as a focus on cost control and higher-value projects.”

This upgrade follows the recent confirmation of Viridien’s corporate rating by Moody’s at “B2” with a stable outlook, which maintained its assessment of the Group’s credit profile while highlighting the increased resilience of its business model and the relevance of its strategy.

Last December, Fitch Ratings had confirmed its rating at “B” with a stable outlook, emphasizing the Company’s improved financial and operational profile.

Jérôme Serve, CFO of Viridien: “We welcome S&P’s upgrade, which reflects the successful execution of our financial roadmap over the past two years, as well as our rigorous and consistent approach to balance sheet deleveraging. We remain firmly focused on further strengthening our financial profile, sustaining strong operating performance and cash generation, and maintaining a disciplined capital allocation policy, in support of value creation for our shareholders”.

***

About Viridien

Viridien (

www.viridiengroup.com

) is an advanced technology, digital and Earth data company that pushes the boundaries of science for a more prosperous and sustainable future. With our ingenuity, drive and deep curiosity we discover new insights, innovations, and solutions that efficiently and responsibly resolve complex natural resources, digital, energy transition and infrastructure challenges. Viridien employs around 3,200 people worldwide and is listed as VIRI on the Euronext Paris SA (ISIN: FR001400PVN6).

Investors contact

VP Investor Relations and Corporate Finance

Alexandre Leroy
[email protected]
+33 6 85 18 44 31

Media contact

Brunswick

Aurélia de Lapeyrouse – +33 6 21 06 40 33
Hugues Boëton – +33 6 79 99 27 15
Tristan Roquet Montégon – +33 6 37 00 52 57
[email protected]

Attachment

• Viridien – Upgraded to “B” by S&P – press release

DUBAI, United Arab Emirates, April 08, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Aurélien Vincent as a Senior Managing Director in the Strategy & Transformation practice within the firm’s Corporate Finance segment.

Mr. Vincent, who is based in Dubai, will lead the firm’s financial services capabilities in the Middle East. He will support clients across the banking, capital markets, asset management and fintech sectors, as well as financial regulators and public and development finance institutions, with structural change, digitisation and transformation programmes and initiatives.

“Aurélien’s appointment shows our ongoing investment to grow our Strategy & Transformation capabilities in the region,” said Antoine Nasr, Head of FTI Consulting Middle East. “His extensive experience advising global financial institutions and regulators, combined with his proven success leading complex transformation programmes, will be invaluable as we continue to help clients across the Middle East navigate change.”

FTI Consulting’s Strategy & Transformation professionals help organisations design and implement strategies that drive growth, improve operational performance and navigate complex regulatory and market environments. Mr. Vincent brings more than 20 years of experience advising financial services institutions on all aspects of complex, end-to-end transformations, including strategy, organisation-wide changes, risk management, digital innovation and ESG initiatives.

Prior to joining FTI Consulting, Mr. Vincent was a Partner at a large strategy consultancy in the Middle East. Earlier in his career, he was an Associate Partner at McKinsey & Company, where he worked across Europe and the Middle East. Before transitioning to strategy consulting, he held senior roles in M&A and wholesale banking at JPMorgan and BNP Paribas in Singapore, London and Paris. He also co-founded and led a renewable energy investment firm.

Commenting on his appointment, Mr. Vincent said, “I look forward to working with colleagues across the firm to help financial institutions in the Middle East navigate an increasingly complex and rapidly evolving landscape. The region’s financial services sector is undergoing significant transformation, and clients need deep expertise to help them deliver sustainable, long-term impact. FTI Consulting’s sector capabilities and collaborative approach provide exactly that.”

About FTI Consulting

FTI Consulting, Inc. is a leading global expert firm for organisations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of December 31, 2025. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalised and independently managed. The Company generated $3.80 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.

200 Aldersgate
Aldersgate Street
London, EC1A 4HD

Investor Contact:

Mollie Hawkes
+1.617.747.1791
[email protected]

Media Contact:

Helen Obi
+44 20 7632 5071
[email protected]

Partnering with Parent Project Muscular Dystrophy to ensure timely access to
the trial for eligible patients

~15,000 children are living with DMD in the U.S.

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil^® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.¹

Ryoncil^® is the first mesenchymal stromal cell (MSC) product approved by FDA, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)². This new registrational trial builds on Ryoncil’s^® proven safety in children, evidence of efficacy in DMD preclinical models, and FDA-approved manufacturing process. Leveraging Ryoncil’s^® anti-inflammatory mechanism of action in SR-aGvHD, Mesoblast aims to reduce the inflammatory cascade characteristic of DMD, preserve muscle function, and slow disease progression.

The trial will randomize 76 patients aged 5 to 9 years to either Ryoncil^® (7 infusions of 2 x 10⁶ cells/kg over 9 months) or placebo, on top of standard of care. The trial’s primary endpoint will be time-to-stand at nine months, a validated FDA endpoint for approval. To support the successful execution of this study, Mesoblast is collaborating with Parent Project Muscular Dystrophy (PPMD) to foster patient identification and trial awareness through proactive community engagement.

“This study represents an important step forward in potentially addressing the inflammatory component of DMD, a major driver of disease progression,” said Aravindhan Veerapandiyan, MD, Director of the Comprehensive Neuromuscular Program at Arkansas Children’s Hospital, and Principal Investigator of the study. “By leveraging the anti-inflammatory effects of Ryoncil, we aim to intervene at a stage where muscle tissue may still be preserved, potentially altering the trajectory of the disease.”

“We are very pleased to have received clearance to proceed directly to a registrational study for DMD based on our preclinical data in DMD animal models and our extensive safety data in children with SR-aGvHD. Our experience with Ryoncil suggests that we may have a unique approach to help with this devastating disease in children,” said Silviu Itescu, Chief Executive of Mesoblast

About Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD) is a X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the muscle leads to loss of ambulation, respiratory failure and cardiomyopathy ultimately leading to death by the third decade.

While gene therapies that replace or increase the missing dystrophin protein are groundbreaking, they are not a complete cure. Chronic inflammation of skeletal and heart muscle remains a major underlying cause of progressive weakness, leading to loss of ambulation, reliance on wheelchair assistance and death in DMD. Corticosteroid use has improved survival but its effects plateau and long-term usage have serious side effects.

About Parent Project Muscular Dystrophy

Parent Project Muscular Dystrophy (PPMD), a leading patient advocacy organization, to support patient identification, education, and trial awareness. The organization was founded in 1994: https://www.parentprojectmd.org/.

About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

References / Footnotes

1. https://cureduchenne.org/about/what-is-duchenne/#:~:text=Prevalence,Cardiac%20Dysfunction
2. Please see the full Prescribing Information at www.ryoncil.com

Forward-Looking Statements

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact: